In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Iterum Therapeutics to Present Data at IDWeek 2025 DUBLIN and CHICAGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that two posters will be presented at the Infectious Disease Society of America’s IDWeek 2025 conference taking place in Atlanta, GA from October 19-22, 2025. The Company will also be conducting a Learning Lounge at IDWeek 2025 on Tuesday, Octob...
Dentsply Sirona to Host Third Quarter Conference Call on November 6th CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, November 6, 2025, at 8:30 am ET to review its financial results for the third quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company’s website at prior to...
Dentsply Sirona Appoints Aldo M. Denti as Chief Commercial Officer and Announces Customer-Centric Organization CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025. The appointment is designed to sharpen the Company’s focus on the customer by aligning its Global Business Units and Commercial Organizations more closely - streamlining how Dentsply Sirona works and delivers. Mr. Den...
Iterum Therapeutics Provides Business Update DUBLIN and CHICAGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today provided a general business update. ORLYNVAHTM Launch Update In partnership with EVERSANA Life Science Services, LLC (“EVERSANA”), ORLYNVAH™ was launched in August 2025 into the community market in the U.S. in targeted territories across seven states.Sales repre...
A director at Perrigo Co maiden bought 1,255 shares at 22.410USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Dentsply Sirona Retains Wellspect Healthcare as a Portfolio Business Following Comprehensive Review of Strategic Alternatives Determined that Wellspect will Deliver Greater Financial and Strategic Benefits to Stockholders as Part of the Company CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company has completed the evaluation of strategic alternatives for its Wellspect Healthcare business (“Wellspect”), which was announced in February 2025. As a part of its review process, Dentsply Si...
Dentsply Sirona to Participate in Upcoming Investor Conferences CHARLOTTE, N.C., Aug. 26, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its participation at upcoming conferences. Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, at 2:35 pm ETBaird Global Healthcare Conference on September 9, 2025, at 1:25 pm ET Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at About ...
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the U.S. commercial launch of ™ (sulopenem etzadroxil and...
Dentsply Sirona Reports Second Quarter 2025 Results Net sales of $936 million decreased (4.9%), decreased (6.7%) in constant currency including a (3.2%) Byte sales impactGAAP gross margin of 52.4%, GAAP net loss per share of ($0.22)Adjusted gross margin of 55.9%, adjusted EBITDA margin of 21.1%, adjusted EPS of $0.52Executed $550 million debt offeringReaffirmed FY25 outlookLeadership transition with Dan Scavilla appointed CEO effective August 1, 2025 and Matt Garth appointed CFO effective May 30, 2025 CHARLOTTE, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Si...
Iterum Therapeutics Reports Second Quarter 2025 Financial Results -- Launch of ORLYNVAHTM Expected August 2025— --Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2025. "We are on track to launch ORLYNVAH™ this month for th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.